Result of General Meeting

April 22, 2024
PDF Version
RNS Number : 5653L
Renalytix PLC
22 April 2024
 

 

Renalytix plc

("Renalytix" or the "Company")

 

Result of General Meeting

 

LONDON and SALT LAKE CITY, 22 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting ("GM") held earlier today all resolutions were passed. Further details of each of the resolutions are set out in Proxy Statement that contains the Notice of General Meeting, which was sent to shareholders on 3 April 2024.

 

The results of the GM are detailed below:

 

Resolution

 

Votes in favour

%

 

Votes against

%

 

Votes withheld










Resolution 1


50,091,780

98.77%


621,329

1.23%


120,431

Resolution 2


45,880,130

90.47%


4,832,979

9.53%


120,431

Resolution 3


50,072,092

98.74%


641,404

1.26%


120,044

Resolution 4


45,853,622

90.42%


4,859,914

9.58%


120,004

 

For further information, please contact:

 

Renalytix plc

James McCullough, CEO

www.renalytix.com

Via Walbrook PR

 


Stifel (Nominated Adviser to the Company)

Nicholas Moore / Alex Price / Nick Harland / Samira Essebiya / Harry Billen

Tel: 02077107600



Investec Bank plc

Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000



Walbrook PR Limited

Paul McManus / Alice Woodings / Charlotte Edgar

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07407 804 654 / 07884 664 686



CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMPPUQUCUPCGAP